MedTrace Logo

Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo

NCT00851344 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2016-11-07

No results posted yet for this study

Summary

A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

DRUG

GSK835726 (10mg)

GSK835726 (10mg) tablet

DRUG

GSK835726 (50mg)

GSK835726 (50mg) tablet

DRUG

GSK835726 (100mg)

GSK835726 (100mg) tablet

DRUG

Cetirizine (10mg)

Cetirizine (10mg) tablet as positive control

OTHER

Placebo

Placebo to match active

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00851344 on ClinicalTrials.gov